VAC Regimen for AML Not Responding to VA
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug combination (VAC) for people with acute myeloid leukemia (AML) who did not improve after standard VA treatment. It is for those who cannot have strong chemotherapy due to age or health problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 59 years old.
- Your leukemia did not respond well (blasts went down by less than half) after treatment with the VA regimen.
- You are not a candidate for intensive chemotherapy, for example because you have a performance status of 2 or 3 (need help with daily activities) or have serious heart, lung, liver, or kidney problems.
- You have not taken chidamide before.
- You do not have any other active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
This trial tests a combination of three drugs (called VAM) in people whose acute myeloid leukemia (AML) is either secondary (came from another blood disorder), therapy-related (caused by previous cancer treatment), or has spread outside the bone marrow (extramedullary disease). It is for patients who have not yet received any treatment for their AML.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
This trial tests a three-drug combination (venetoclax, chidamide, and azacitidine) followed by another combination (decitabine plus MAG) for older adults with untreated acute myeloid leukemia (AML) who cannot have standard chemotherapy. It aims to offer a gentler but effective treatment option.
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
This study tests whether giving a drug called VA (which includes a vitamin A derivative and a medication that helps the immune system fight cancer) after a stem cell transplant can help keep leukemia or MDS from coming back. It is for patients who are already in remission after their transplant.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.